Gastric Cancer Diagnostics Market

Gastric Cancer Diagnostics Market (Diagnostic Test Type: Imaging Tests, Molecular Tests, Biopsy and Others; Disease Type: Adenocarcinoma, Gastrointestinal stromal tumors (GIST), Gastrointestinal Neuroendocrine (Carcinoid) Tumors and Others; and End-user: Hospital Laboratories, Diagnostic Centers, Academic and Research Institutes and Others) – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025-2035

Gastric Cancer Diagnostics Market Outlook 2035

The global gastric cancer diagnostics market size was valued at US$ 3.5 billion in 2024 and is projected to reach US$ 6.9 billion by 2035, expanding at a CAGR of 6.4% from 2025 to 2035. The market growth is driven by the rising incidence of gastric cancer, increasing risk factors like H. pylori infections, obesity, and smoking, and advancements in diagnostic technology.

Market Size & Highlights

The gastric cancer diagnostics market reached US$ 3.5 Billion in 2024.
The market is expected to climb to US$ 6.9 Billion by 2035.
The gastric cancer diagnostics industry is anticipated to expand at a CAGR of 6.4% from 2025 to 2035.
Top companies in the market include Abbott, Agilent Technologies, Inc., and F. Hoffmann-La Roche AG
North America dominated the market in 2024, holding the largest revenue share of 45.7%.
By diagnostic test type, the imaging tests segment held the major market share of 74.8% in 2024.

Gastric Cancer Diagnostics Market By Revanue

Analysts’ Viewpoint regarding Gastric Cancer Diagnostics Market

The increasing expenditure on healthcare and improved public healthcare policy support for early detection and screening are significant drivers bolstering the gastric cancer diagnostics market. Increased funding of public and private payers into preventive oncology has increased the accessibility of diagnostic tests.

National screening programs and campaigns have driven endoscopic and non-invasive screening tests to greater use, so that diagnostics are a central part of routine care pathways. Increased risk-sharing mechanisms and facilitative reimbursement models reduce out-of-pocket expenditure further, allowing for deeper market penetration in urban and semi-urban geographies and inducing sustained diagnostic consumption and commercialization.

A second salient driver is greater capital inflow and harmonized partnership throughout the healthcare value system, which propels market development more rapidly. Further venture capital investment, private equity investment, and public–private partnership provides commercial scale-up and distribution networks, especially in the underserved regions. In particular, payers and health systems are increasingly integrating diagnostics into value-based care models to enable earlier testing and improve long-term outcomes at lower cost.

The recent trends have shifted their focus toward minimally invasive, patient-centric diagnostic pathways, and simplification of service delivery. Practitioners have started to use more blood-based assays and multiplex biomarker panels for their investigation.

Additionally, decentralized testing and improved sample logistics have been implemented to shorten turnaround time. The commercial priorities circle around generating real-world evidence and conducting health-economic analyses to show the usefulness of the clinic and to help with reimbursement negotiations. Collaborative pilots between healthcare systems, together with the diagnostics developers and regulatory authorities, are promoting clinical integration and the acceptance among both clinicians and payers.

Gastric Cancer Diagnostics Market Introduction

Gastric cancer refers to the abnormalities wherein cancer cells grow in stomach lining. The leading risk factors for gastric cancer are excessive body weight, consumption of a diet mainly consisting of processed foods, and genetic predispositions. There are multiple methods for diagnosis, which are used to verify and stage the condition. Typical testing methods involve endoscopy with biopsy to examine stomach tissue, imaging tests like CT Scans and PET Scans to determine whether the tumor has spread, and blood tests for tumor markers.

The gastric cancer diagnostics begins with clinical assessment and non-invasive tests. These tests involve blood sampling to establish certain tumor markers, stool examinations, and imaging tests to determine visualization of stomach abnormalities. These screening tests help identify suspicious lesions that further require investigation.

Usually, confirmation of disease is achieved through endoscopy and biopsy, where a sample of the stomach lining is collected and it undergoes histological examination to detect cancer cells. Besides, molecular and genetic tests may be used to ascertain gene mutations and biomarkers helpful in therapy, e.g., HER2 or PD-L1 expression.

The development of molecular diagnostics and precision oncology has significantly improved the early detection of gastric cancer. The adoption of liquid biopsies, genomic profiling, and AI-powered diagnostic tools has led to the customization of screening strategies that provide not only diagnostic accuracy but also patient management.

Attribute	Detail
Gastric Cancer Diagnostics Market Drivers	Rising Prevalence of Gastric Cancer Technological Advancements in Diagnostic Tools

Rising Prevalence of Gastric Cancer is Skyrocketing the Gastric Cancer Diagnostics Market Share

The increasing prevalence of gastric cancer is a significant driver fostering the gastric cancer diagnostics market. Increased prevalence rates generate increased demand for screening programs and diagnostic technologies for the detection of the disease at earlier stages, thus improving survival rates. Health systems are increasingly emphasizing on early intervention, thereby encouraging the utilization of a wide array of diagnostic modalities, including imaging, endoscopy, histopathology, and molecular testing, in an attempt to provide timely and accurate disease management.

With increased number of individuals affected, clinics, and hospitals are expanding their diagnostic capabilities to treat the growing patient pool. This has led to more investment in diagnostic equipment, like high-resolution endoscopes, and laboratory equipment. Increased capacity of diagnostics allows clinicians to treat more effectively and efficiently, reducing the diagnostic delay and facilitating population-level screening programs with consistent demand for diagnostic service.

The rising incidence of gastric cancer also prompts healthcare policy makers and insurers to include gastric cancer diagnostics as part of their preventive care programs. The reimbursement policies and national screening guidelines that are issued are progressively favoring regular testing, especially for the high-risk groups, thus giving more ground for the use of diagnostic tests. Early diagnosis lowers treatment costs in the long run, thereby motivating healthcare systems to allocate funds in the right and easily scalable diagnostic tools, which guarantee better patient outcomes.

Moreover, patient knowledge that comes as a result of the rising disease prevalence is also positively impacting the market. Various awareness campaigns and educational activities are encouraging individuals to get tested, thus, increasing the demand for diagnostic solutions. The clinical need, policy support, and patient-driven demand, are the main forces that are pushing forward the gastric cancer diagnostics market, thus, opening up opportunities for further innovation and growth.

Technological Advancements in Diagnostic Tools is Propelling the Gastric Cancer Diagnostics Market Share

The innovation in diagnostic technologies are another significant factor that greatly contributes to the gastric cancer diagnostics market growth. The imaging techniques that aid in the innovative diagnostic procedures such as high-resolution endoscopy, narrow-band imaging, and endoscopic ultrasound have indeed revolutionized the doctors’ ability to visualize tumors and the other abnormal growths in stomach lining. Besides, such instruments will not only eliminate errors in diagnosis but will also facilitate the discovery of early-stage diseases, which is very important in ensuring better patient outcomes.

The introduction of genetics and molecular diagnostics like PCR, NGS, and immunohistochemistry have essentially changed the way gastric cancer is diagnosed. These kinds of tests provide accurate information about tumor biology and are sensitive in identifying the presence of biomarkers like HER2, and PD-L1. As a result, the development of personalized treatment regimens and the employment of targeted therapy become feasible.

Integration of artificial intelligence (AI) and machine learning into diagnostic workflows is a major factor that is contributing to the market expansion. AI-enabled image processing, predictive modeling, and pattern recognition have empowered the medical professionals to find the very minute abnormalities that can easily escape a manual check. These solution providers not only boost the diagnostic effectiveness, but also help to shorten the overall time of turnaround, thus reducing the total number of errors, which in turn enhances the value of these diagnostic tools.

Moreover, point-of-care testing as well as minimally invasive diagnostic methods, are widening the reach of gastric cancer diagnostics. Mobile endoscopic devices, liquid biopsies, and rapid biomarker assays are enabling testing to be done in remote areas, rendering convenience and facilitating intervention at an earlier disease stage. Collectively, these technological advancements create a customer base that is strong, promote market penetration, and decisively accelerate the gastric cancer diagnostics market.

Imaging Tests Leading Global Gastric Cancer Diagnostics Market

Gastric Cancer Diagnostics Market By Test Type

Imaging tests are leading the gastric cancer diagnostics market as they are an essential part of early detection, localization of tumor, and staging accuracy. Some of the techniques like computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET) allow a detailed visualization of gastric lesions, which makes it possible for doctors to measure the size, extension, and treatment response of the tumor.

Their features such as being non-invasive, having high diagnostic precision, and ability to guide the surgical or therapeutic planning add more to their clinical utility. The continuous innovations in imaging technologies, which comprise AI-based interpretation and enhanced resolution systems have raised diagnostic reliability and thus imaging tests have become the preferred choice across all healthcare facilities, worldwide.=

Regional Outlook of Gastric Cancer Diagnostics Market

Gastric Cancer Diagnostics Market By Region

Attribute	Detail
Leading Region	North America

As per the latest gastric cancer diagnostics market analysis, North America dominated in 2024, capturing a market share of 45.7%. This is attributed to the region’s well-implemented healthcare infrastructure and high healthcare expenditure. Routine diagnostic facilities, universal implementation of screening programs, and accessibility of cutting-edge technologies, like high-resolution endoscopy, molecular testing, and AI-assisted diagnostics, are some of the key elements that further contribute in the region’s dominance. Additionally, rigorous regulatory frameworks and appealing reimbursement policies facilitate the acceptance of innovative diagnostic solutions thus ensuring an extensive market penetration.

Moreover, the growing awareness among patients and doctors about early detection, coupled with the strategic moves of healthcare providers’ in incorporating complete diagnostic protocols, drives consistent demand. Partnerships between healthcare systems and diagnostic developers also reinforce the hold of North America on the gastric cancer diagnostics market.

Analysis of Key Players in Gastric Cancer Diagnostics Market

Companies that operate in the gastric cancer diagnostics market focus on strategic initiatives like elaborating comprehensive testing portfolios, regional distribution networks expanding, forming partnerships with healthcare providers, implementing reimbursement support programs, investing in real-world evidence studies, and launching clinician education and patient awareness campaigns with the purpose of increasing market penetration.

Abbott, Agilent Technologies, Inc., F. Hoffmann-La Roche Ltd, MiRXES Pte Ltd., Endofotonics Pte Ltd., Hipro Biotechnology Co.,Ltd., Fulgent Genetics, NeoGenomics Laboratories, Samsung Medison Co., Ltd., Natera, Inc., Randox Laboratories Ltd., GE HealthCare, Koninklijke Philips N.V, CANON MEDICAL SYSTEMS CORPORATION, and Promega Corporation are some of the leading players operating in the global gastric cancer diagnostics market.

Each of these players has been profiled in the gastric cancer diagnostics market research report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.

Key Developments in Gastric Cancer Diagnostics Market

In August 2025, Akeso, Inc. announced the enrolment of first patient in the phase III pivotal clinical trial, COMPASSION-33, for evaluation of a first-in-class PD-1/CTLA-4 bispecific antibody, cadonilimab, in combination with chemotherapy, for the perioperative treatment of resectable gastric/gastroesophageal junction (G/GEJ) adenocarcinoma.
In March 2024, Astellas Pharma Inc. announced that the company received approval for VYLOYTM (zolbetuximab), an anti-claudin 18.2 (CLDN18.2) monoclonal antibody, from Japan's Ministry of Health, Labour and Welfare (MHLW), for the treatment of CLDN18.2-positive, unresectable, advanced or recurrent gastric cancer.

Gastric Cancer Diagnostics Market Snapshot

Attribute	Detail
Size in 2024	US$ 3.5 Bn
Forecast Value in 2035	US$ 6.9 Bn
CAGR	6.4%
Forecast Period	2025–2035
Historical Data Available for	2020–2023
Quantitative Units	US$ Bn
Gastric Cancer Diagnostics Market Analysis	It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, value chain analysis, and key trend analysis.
Competition Landscape	Competition Matrix Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials
Format	Electronic (PDF) + Excel
Segmentation	Diagnostic Test Type Imaging Tests Upper gastrointestinal (GI) series Computed tomography (CT) Scan Endoscopic Ultrasound Positron emission tomography (PET) Scan Magnetic resonance imaging (MRI) Molecular Tests HER2 MSI/MMR PD-L1 expression Others (CDH1 Mutations, etc.) Biopsy Others (Tumor Marker Tests, etc.) Disease Type Adenocarcinoma Gastrointestinal stromal tumors (GIST) Gastrointestinal Neuroendocrine (Carcinoid) Tumors Others (squamous cell carcinomas, etc.) End-user Hospital Laboratories Diagnostic Centers Academic and Research Institutes Others (Imaging Centers, etc.)
Regions Covered	North America Europe Asia Pacific Latin America Middle East & Africa
Countries Covered	U.S. Canada Germany U.K. France Italy Spain The Netherlands China Australia India Japan South Korea ASEAN Brazil Mexico Argentina GCC Countries South Africa
Companies Profiled	Abbott Agilent Technologies, Inc. F. Hoffmann-La Roche Ltd MiRXES Pte Ltd. Endofotonics Pte Ltd. Hipro Biotechnology Co., Ltd. Fulgent Genetics NeoGenomics Laboratories Samsung Medison Co., Ltd. Natera, Inc. Randox Laboratories Ltd. GE HealthCare Koninklijke Philips N.V CANON MEDICAL SYSTEMS CORPORATION Promega Corporation
Customization Scope	Available upon request
Pricing	Available upon request

Frequently Asked Questions

How big was the global gastric cancer diagnostics market in 2024?

The global gastric cancer diagnostics market was valued at US$ 3.5 Bn in 2024

How big will the global gastric cancer diagnostics industry be in 2035?

The global gastric cancer diagnostics industry is projected to reach more than US$ 6.9 Bn by the end of 2035.

What are the factors driving the gastric cancer diagnostics market?

The rising incidence of gastric cancer, increasing risk factors like H. pylori infections, obesity, and smoking, advances in diagnostic technology, and rising focus on early detection through screening programs are some of the factors driving the expansion of gastric cancer diagnostics market.

What will be the CAGR of the global gastric cancer diagnostics industry during the forecast period?

The CAGR is anticipated to be 6.4% from 2025 to 2035

Who are the prominent players in the global gastric cancer diagnostics market?

Preface
- Market Definition and Scope
- Market Segmentation
- Key Research Objectives
- Research Highlights
Assumptions and Research Methodology
Executive Summary: Global Gastric Cancer Diagnostics Market
Market Overview
- Introduction
  - Segment Definition
- Overview
- Market Dynamics
  - Drivers
  - Restraints
  - Opportunities
- Global Gastric Cancer Diagnostics Market Analysis and Forecast, 2020 - 2035
  - Market Revenue Projections (US$ Bn)
Key Insights
- Healthcare Expenditure across Key Countries / Regions
- Recent Advancements in Gastric Cancer Diagnostics
- Pricing Trends for Gastric Cancer Diagnostics
- Regulatory Scenario across Key Regions / Countries
- Reimbursement Landscape across Key Regions / Countries
- PORTER’s Five Forces Analysis
- PESTLE Analysis
- Go-to-Market Strategy for New Market Entrants
- Key Purchase Metrics for End-users
- Key Industry Events (Partnership, Collaborations, Product approvals, merger & acquisitions)
- Benchmarking of the Products Offered by the Leading Competitors
Global Gastric Cancer Diagnostics Market Analysis and Forecast, by Diagnostic Test Type
- Introduction & Definition
- Key Findings/Developments
- Market Value Forecast, by Diagnostic Test Type, 2020 - 2035
  - Imaging Tests
    - Upper gastrointestinal (GI) series
    - Computed tomography (CT) Scan
    - Endoscopic Ultrasound
    - Positron emission tomography (PET) Scan
    - Magnetic resonance imaging (MRI)
  - Molecular Tests
    - HER2
    - MSI/MMR
    - PD-L1 expression
    - Others (CDH1 Mutations, etc.)
  - Biopsy
  - Others
- Market Attractiveness Analysis, by Diagnostic Test Type
Global Gastric Cancer Diagnostics Market Analysis and Forecast, by Disease Type
- Introduction & Definition
- Key Findings/Developments
- Market Value Forecast, by Disease Type, 2020 - 2035
  - Adenocarcinoma
  - Gastrointestinal stromal tumors (GIST)
  - Gastrointestinal Neuroendocrine (Carcinoid) Tumors
  - Others
- Market Attractiveness Analysis, by Disease Type
Global Gastric Cancer Diagnostics Market Analysis and Forecast, by End-user
- Introduction & Definition
- Key Findings/Developments
- Market Value Forecast, by End-user, 2020 - 2035
  - Hospital Laboratories
  - Diagnostic Centers
  - Academic and Research Institutes
  - Others
- Market Attractiveness Analysis, by End-user
Global Gastric Cancer Diagnostics Market Analysis and Forecast, by Region
- Key Findings
- Market Value Forecast, by Region, 2020 - 2035
  - North America
  - Europe
  - Asia Pacific
  - Latin America
  - Middle East & Africa
- Market Attractiveness Analysis, by Region
North America Gastric Cancer Diagnostics Market Analysis and Forecast
- Introduction
  - Key Findings
- Market Value Forecast, by Diagnostic Test Type, 2020 - 2035
  - Imaging Tests
    - Upper gastrointestinal (GI) series
    - Computed tomography (CT) Scan
    - Endoscopic Ultrasound
    - Positron emission tomography (PET) Scan
    - Magnetic resonance imaging (MRI)
  - Molecular Tests
    - HER2
    - MSI/MMR
    - PD-L1 expression
    - Others (CDH1 Mutations, etc.)
  - Biopsy
  - Others
- Market Value Forecast, by Disease Type, 2020 - 2035
  - Adenocarcinoma
  - Gastrointestinal stromal tumors (GIST)
  - Gastrointestinal Neuroendocrine (Carcinoid) Tumors
  - Others
- Market Value Forecast, by End-user, 2020 - 2035
  - Hospital Laboratories
  - Diagnostic Centers
  - Academic and Research Institutes
  - Others
- Market Value Forecast, by Country, 2020 - 2035
  - U.S.
  - Canada
- Market Attractiveness Analysis
  - By Diagnostic Test Type
  - By Disease Type
  - By End-user
  - By Country
Europe Gastric Cancer Diagnostics Market Analysis and Forecast
- Introduction
  - Key Findings
- Market Value Forecast, by Diagnostic Test Type, 2020 - 2035
  - Imaging Tests
    - Upper gastrointestinal (GI) series
    - Computed tomography (CT) Scan
    - Endoscopic Ultrasound
    - Positron emission tomography (PET) Scan
    - Magnetic resonance imaging (MRI)
  - Molecular Tests
    - HER2
    - MSI/MMR
    - PD-L1 expression
    - Others (CDH1 Mutations, etc.)
  - Biopsy
  - Others
- Market Value Forecast, by Disease Type, 2020 - 2035
  - Adenocarcinoma
  - Gastrointestinal stromal tumors (GIST)
  - Gastrointestinal Neuroendocrine (Carcinoid) Tumors
  - Others
- Market Value Forecast, by End-user, 2020 - 2035
  - Hospital Laboratories
  - Diagnostic Centers
  - Academic and Research Institutes
  - Others
- Market Value Forecast, by Country/Sub-region, 2020 - 2035
  - UK
  - Germany
  - France
  - Italy
  - Spain
  - The Netherlands
  - Rest of Europe
- Market Attractiveness Analysis
  - By Diagnostic Test Type
  - By Disease Type
  - By End-user
  - By Country/Sub-region
Asia Pacific Gastric Cancer Diagnostics Market Analysis and Forecast
- Introduction
  - Key Findings
- Market Value Forecast, by Diagnostic Test Type, 2020 - 2035
  - Imaging Tests
    - Upper gastrointestinal (GI) series
    - Computed tomography (CT) Scan
    - Endoscopic Ultrasound
    - Positron emission tomography (PET) Scan
    - Magnetic resonance imaging (MRI)
  - Molecular Tests
    - HER2
    - MSI/MMR
    - PD-L1 expression
    - Others (CDH1 Mutations, etc.)
  - Biopsy
  - Others
- Market Value Forecast, by Disease Type, 2020 - 2035
  - Adenocarcinoma
  - Gastrointestinal stromal tumors (GIST)
  - Gastrointestinal Neuroendocrine (Carcinoid) Tumors
  - Others
- Market Value Forecast, by End-user, 2020 - 2035
  - Hospital Laboratories
  - Diagnostic Centers
  - Academic and Research Institutes
  - Others
- Market Value Forecast, by Country/Sub-region, 2020 - 2035
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
- Market Attractiveness Analysis
  - By Diagnostic Test Type
  - By Disease Type
  - By End-user
  - By Country/Sub-region
Latin America Gastric Cancer Diagnostics Market Analysis and Forecast
- Introduction
  - Key Findings
- Market Value Forecast, by Diagnostic Test Type, 2020 - 2035
  - Imaging Tests
    - Upper gastrointestinal (GI) series
    - Computed tomography (CT) Scan
    - Endoscopic Ultrasound
    - Positron emission tomography (PET) Scan
    - Magnetic resonance imaging (MRI)
  - Molecular Tests
    - HER2
    - MSI/MMR
    - PD-L1 expression
    - Others (CDH1 Mutations, etc.)
  - Biopsy
  - Others
- Market Value Forecast, by Disease Type, 2020 - 2035
  - Adenocarcinoma
  - Gastrointestinal stromal tumors (GIST)
  - Gastrointestinal Neuroendocrine (Carcinoid) Tumors
  - Others
- Market Value Forecast, by End-user, 2020 - 2035
  - Hospital Laboratories
  - Diagnostic Centers
  - Academic and Research Institutes
  - Others
- Market Value Forecast, by Country/Sub-region, 2020 - 2035
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
- Market Attractiveness Analysis
  - By Diagnostic Test Type
  - By Disease Type
  - By End-user
  - By Country/Sub-region
Middle East & Africa Gastric Cancer Diagnostics Market Analysis and Forecast
- Introduction
  - Key Findings
- Market Value Forecast, by Diagnostic Test Type, 2020 - 2035
  - Imaging Tests
    - Upper gastrointestinal (GI) series
    - Computed tomography (CT) Scan
    - Endoscopic Ultrasound
    - Positron emission tomography (PET) Scan
    - Magnetic resonance imaging (MRI)
  - Molecular Tests
    - HER2
    - MSI/MMR
    - PD-L1 expression
    - Others (CDH1 Mutations, etc.)
  - Biopsy
  - Others
- Market Value Forecast, by Disease Type, 2020 - 2035
  - Adenocarcinoma
  - Gastrointestinal stromal tumors (GIST)
  - Gastrointestinal Neuroendocrine (Carcinoid) Tumors
  - Others
- Market Value Forecast, by End-user, 2020 - 2035
  - Hospital Laboratories
  - Diagnostic Centers
  - Academic and Research Institutes
  - Others
- Market Value Forecast, by Country/Sub-region, 2020 - 2035
  - GCC Countries
  - South Africa
  - Rest of Middle East & Africa
- Market Attractiveness Analysis
  - By Diagnostic Test Type
  - By Disease Type
  - By End-user
  - By Country/Sub-region
Competition Landscape
- Market Player – Competition Matrix (By Tier and Size of Companies)
- Market Share Analysis, by Company (2024)
- Company Profiles
  - Abbott
    - Company Overview
    - Financial Overview
    - Financial Overview
    - Business Strategies
    - Recent Developments
  - Agilent Technologies, Inc.
    - Company Overview
    - Financial Overview
    - Financial Overview
    - Business Strategies
    - Recent Developments
  - F. Hoffmann-La Roche Ltd
    - Company Overview
    - Financial Overview
    - Financial Overview
    - Business Strategies
    - Recent Developments
  - MiRXES Pte Ltd.
    - Company Overview
    - Financial Overview
    - Financial Overview
    - Business Strategies
    - Recent Developments
  - Endofotonics Pte Ltd.
    - Company Overview
    - Financial Overview
    - Financial Overview
    - Business Strategies
    - Recent Developments
  - Hipro Biotechnology Co., Ltd.
    - Company Overview
    - Financial Overview
    - Financial Overview
    - Business Strategies
    - Recent Developments
  - Fulgent Genetics
    - Company Overview
    - Financial Overview
    - Financial Overview
    - Business Strategies
    - Recent Developments
  - NeoGenomics Laboratories
    - Company Overview
    - Financial Overview
    - Financial Overview
    - Business Strategies
    - Recent Developments
  - Samsung Medison Co., Ltd.
    - Company Overview
    - Financial Overview
    - Financial Overview
    - Business Strategies
    - Recent Developments
  - Natera, Inc.
    - Company Overview
    - Financial Overview
    - Financial Overview
    - Business Strategies
    - Recent Developments
  - Randox Laboratories Ltd.
    - Company Overview
    - Financial Overview
    - Financial Overview
    - Business Strategies
    - Recent Developments
  - GE HealthCare
    - Company Overview
    - Financial Overview
    - Financial Overview
    - Business Strategies
    - Recent Developments
  - Koninklijke Philips N.V
    - Company Overview
    - Financial Overview
    - Financial Overview
    - Business Strategies
    - Recent Developments
  - CANON MEDICAL SYSTEMS CORPORATION
    - Company Overview
    - Financial Overview
    - Financial Overview
    - Business Strategies
    - Recent Developments
  - Promega Corporation
    - Company Overview
    - Financial Overview
    - Financial Overview
    - Business Strategies
    - Recent Developments

List of Tables

Table 01: Global Gastric Cancer Diagnostics Market Value (US$ Bn) Forecast, By Diagnostic Test Type, 2020 to 2035
Table 02: Global Gastric Cancer Diagnostics Market Value (US$ Bn) Forecast, By Imaging Tests, 2020 to 2035
Table 03: Global Gastric Cancer Diagnostics Market Value (US$ Bn) Forecast, By Molecular Tests, 2020 to 2035
Table 04: Global Gastric Cancer Diagnostics Market Value (US$ Bn) Forecast, By Disease Type, 2020 to 2035
Table 05: Global Gastric Cancer Diagnostics Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 06: Global Gastric Cancer Diagnostics Market Value (US$ Bn) Forecast, By Region, 2020 to 2035
Table 07: North America Gastric Cancer Diagnostics Market Value (US$ Bn) Forecast, by Country, 2020 to 2035
Table 08: North America Gastric Cancer Diagnostics Market Value (US$ Bn) Forecast, By Diagnostic Test Type, 2020 to 2035
Table 09: North America Gastric Cancer Diagnostics Market Value (US$ Bn) Forecast, By Imaging Tests, 2020 to 2035
Table 10: North America Gastric Cancer Diagnostics Market Value (US$ Bn) Forecast, By Molecular Tests, 2020 to 2035
Table 11: North America Gastric Cancer Diagnostics Market Value (US$ Bn) Forecast, By Disease Type, 2020 to 2035
Table 12: North America Gastric Cancer Diagnostics Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 13: Europe Gastric Cancer Diagnostics Market Value (US$ Bn) Forecast, by Country/Sub-region, 2020 to 2035
Table 14: Europe Gastric Cancer Diagnostics Market Value (US$ Bn) Forecast, By Diagnostic Test Type, 2020 to 2035
Table 15: Europe Gastric Cancer Diagnostics Market Value (US$ Bn) Forecast, By Imaging Tests, 2020 to 2035
Table 16: Europe Gastric Cancer Diagnostics Market Value (US$ Bn) Forecast, By Molecular Tests, 2020 to 2035
Table 17: Europe Gastric Cancer Diagnostics Market Value (US$ Bn) Forecast, By Disease Type, 2020 to 2035
Table 18: Europe Gastric Cancer Diagnostics Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 19: Asia Pacific Gastric Cancer Diagnostics Market Value (US$ Bn) Forecast, by Country/Sub-region, 2020 to 2035
Table 20: Asia Pacific Gastric Cancer Diagnostics Market Value (US$ Bn) Forecast, By Diagnostic Test Type, 2020 to 2035
Table 21: Asia Pacific Gastric Cancer Diagnostics Market Value (US$ Bn) Forecast, By Imaging Tests, 2020 to 2035
Table 22: Asia Pacific Gastric Cancer Diagnostics Market Value (US$ Bn) Forecast, By Molecular Tests, 2020 to 2035
Table 23: Asia Pacific Gastric Cancer Diagnostics Market Value (US$ Bn) Forecast, By Disease Type, 2020 to 2035
Table 24: Asia Pacific Gastric Cancer Diagnostics Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 25: Latin America Gastric Cancer Diagnostics Market Value (US$ Bn) Forecast, by Country/Sub-region, 2020 to 2035
Table 26: Latin America Gastric Cancer Diagnostics Market Value (US$ Bn) Forecast, By Diagnostic Test Type, 2020 to 2035
Table 27: Latin America Gastric Cancer Diagnostics Market Value (US$ Bn) Forecast, By Imaging Tests, 2020 to 2035
Table 28: Latin America Gastric Cancer Diagnostics Market Value (US$ Bn) Forecast, By Molecular Tests, 2020 to 2035
Table 29: Latin America Gastric Cancer Diagnostics Market Value (US$ Bn) Forecast, By Disease Type, 2020 to 2035
Table 30: Latin America Gastric Cancer Diagnostics Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
Table 31: Middle East & Africa Gastric Cancer Diagnostics Market Value (US$ Bn) Forecast, by Country/Sub-region, 2020 to 2035
Table 32: Middle East & Africa Gastric Cancer Diagnostics Market Value (US$ Bn) Forecast, By Diagnostic Test Type, 2020 to 2035
Table 33: Middle East & Africa Gastric Cancer Diagnostics Market Value (US$ Bn) Forecast, By Imaging Tests, 2020 to 2035
Table 34: Middle East & Africa Gastric Cancer Diagnostics Market Value (US$ Bn) Forecast, By Molecular Tests, 2020 to 2035
Table 35: Middle East & Africa Gastric Cancer Diagnostics Market Value (US$ Bn) Forecast, By Disease Type, 2020 to 2035
Table 36: Middle East & Africa Gastric Cancer Diagnostics Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035

List of Figures

Figure 01: Global Gastric Cancer Diagnostics Market Value Share Analysis, By Diagnostic Test Type, 2024 and 2035
Figure 02: Global Gastric Cancer Diagnostics Market Attractiveness Analysis, By Diagnostic Test Type, 2025 to 2035
Figure 03: Global Gastric Cancer Diagnostics Market Revenue (US$ Bn), by Imaging Tests, 2020 to 2035
Figure 04: Global Gastric Cancer Diagnostics Market Revenue (US$ Bn), by Molecular Tests, 2020 to 2035
Figure 05: Global Gastric Cancer Diagnostics Market Revenue (US$ Bn), by Biopsy, 2020 to 2035
Figure 06: Global Gastric Cancer Diagnostics Market Revenue (US$ Bn), by Others, 2020 to 2035
Figure 07: Global Gastric Cancer Diagnostics Market Value Share Analysis, By Disease Type, 2024 and 2035
Figure 08: Global Gastric Cancer Diagnostics Market Attractiveness Analysis, By Disease Type, 2025 to 2035
Figure 09: Global Gastric Cancer Diagnostics Market Revenue (US$ Bn), by Adenocarcinoma, 2020 to 2035
Figure 10: Global Gastric Cancer Diagnostics Market Revenue (US$ Bn), by Gastrointestinal stromal tumors (GIST), 2020 to 2035
Figure 11: Global Gastric Cancer Diagnostics Market Revenue (US$ Bn), by Gastrointestinal Neuroendocrine (Carcinoid) Tumors, 2020 to 2035
Figure 12: Global Gastric Cancer Diagnostics Market Revenue (US$ Bn), by Others, 2020 to 2035
Figure 13: Global Gastric Cancer Diagnostics Market Value Share Analysis, By End-user, 2024 and 2035
Figure 14: Global Gastric Cancer Diagnostics Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 15: Global Gastric Cancer Diagnostics Market Revenue (US$ Bn), by Hospital Laboratories, 2020 to 2035
Figure 16: Global Gastric Cancer Diagnostics Market Revenue (US$ Bn), by Diagnostic Centers, 2020 to 2035
Figure 17: Global Gastric Cancer Diagnostics Market Revenue (US$ Bn), by Academic and Research Institutes, 2020 to 2035
Figure 18: Global Gastric Cancer Diagnostics Market Revenue (US$ Bn), by Others, 2020 to 2035
Figure 19: Global Gastric Cancer Diagnostics Market Value Share Analysis, By Region, 2024 and 2035
Figure 20: Global Gastric Cancer Diagnostics Market Attractiveness Analysis, By Region, 2025 to 2035
Figure 21: North America Gastric Cancer Diagnostics Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 22: North America Gastric Cancer Diagnostics Market Value Share Analysis, by Country, 2024 and 2035
Figure 23: North America Gastric Cancer Diagnostics Market Attractiveness Analysis, by Country, 2025 to 2035
Figure 24: North America Gastric Cancer Diagnostics Market Value Share Analysis, By Diagnostic Test Type, 2024 and 2035
Figure 25: North America Gastric Cancer Diagnostics Market Attractiveness Analysis, By Diagnostic Test Type, 2025 to 2035
Figure 26: North America Gastric Cancer Diagnostics Market Value Share Analysis, By Disease Type, 2024 and 2035
Figure 27: North America Gastric Cancer Diagnostics Market Attractiveness Analysis, By Disease Type, 2025 to 2035
Figure 28: North America Gastric Cancer Diagnostics Market Value Share Analysis, By End-user, 2024 and 2035
Figure 29: North America Gastric Cancer Diagnostics Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 30: Europe Gastric Cancer Diagnostics Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 31: Europe Gastric Cancer Diagnostics Market Value Share Analysis, by Country/Sub-region, 2024 and 2035
Figure 32: Europe Gastric Cancer Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2025 to 2035
Figure 33: Europe Gastric Cancer Diagnostics Market Value Share Analysis, By Diagnostic Test Type, 2024 and 2035
Figure 34: Europe Gastric Cancer Diagnostics Market Attractiveness Analysis, By Diagnostic Test Type, 2025 to 2035
Figure 35: Europe Gastric Cancer Diagnostics Market Value Share Analysis, By Disease Type, 2024 and 2035
Figure 36: Europe Gastric Cancer Diagnostics Market Attractiveness Analysis, By Disease Type, 2025 to 2035
Figure 37: Europe Gastric Cancer Diagnostics Market Value Share Analysis, By End-user, 2024 and 2035
Figure 38: Europe Gastric Cancer Diagnostics Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 39: Asia Pacific Gastric Cancer Diagnostics Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 40: Asia Pacific Gastric Cancer Diagnostics Market Value Share Analysis, by Country/Sub-region, 2024 and 2035
Figure 41: Asia Pacific Gastric Cancer Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2025 to 2035
Figure 42: Asia Pacific Gastric Cancer Diagnostics Market Value Share Analysis, By Diagnostic Test Type, 2024 and 2035
Figure 43: Asia Pacific Gastric Cancer Diagnostics Market Attractiveness Analysis, By Diagnostic Test Type, 2025 to 2035
Figure 44: Asia Pacific Gastric Cancer Diagnostics Market Value Share Analysis, By Disease Type, 2024 and 2035
Figure 45: Asia Pacific Gastric Cancer Diagnostics Market Attractiveness Analysis, By Disease Type, 2025 to 2035
Figure 46: Asia Pacific Gastric Cancer Diagnostics Market Value Share Analysis, By End-user, 2024 and 2035
Figure 47: Asia Pacific Gastric Cancer Diagnostics Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 48: Latin America Gastric Cancer Diagnostics Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 49: Latin America Gastric Cancer Diagnostics Market Value Share Analysis, by Country/Sub-region, 2024 and 2035
Figure 50: Latin America Gastric Cancer Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2025 to 2035
Figure 51: Latin America Gastric Cancer Diagnostics Market Value Share Analysis, By Diagnostic Test Type, 2024 and 2035
Figure 52: Latin America Gastric Cancer Diagnostics Market Attractiveness Analysis, By Diagnostic Test Type, 2025 to 2035
Figure 53: Latin America Gastric Cancer Diagnostics Market Value Share Analysis, By Disease Type, 2024 and 2035
Figure 54: Latin America Gastric Cancer Diagnostics Market Attractiveness Analysis, By Disease Type, 2025 to 2035
Figure 55: Latin America Gastric Cancer Diagnostics Market Value Share Analysis, By End-user, 2024 and 2035
Figure 56: Latin America Gastric Cancer Diagnostics Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 57: Middle East & Africa Gastric Cancer Diagnostics Market Value (US$ Bn) Forecast, 2020 to 2035
Figure 58: Middle East & Africa Gastric Cancer Diagnostics Market Value Share Analysis, by Country/Sub-region, 2024 and 2035
Figure 59: Middle East & Africa Gastric Cancer Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2025 to 2035
Figure 60: Middle East & Africa Gastric Cancer Diagnostics Market Value Share Analysis, By Diagnostic Test Type, 2024 and 2035
Figure 61: Middle East & Africa Gastric Cancer Diagnostics Market Attractiveness Analysis, By Diagnostic Test Type, 2025 to 2035
Figure 62: Middle East & Africa Gastric Cancer Diagnostics Market Value Share Analysis, By Disease Type, 2024 and 2035
Figure 63: Middle East & Africa Gastric Cancer Diagnostics Market Attractiveness Analysis, By Disease Type, 2025 to 2035
Figure 64: Middle East & Africa Gastric Cancer Diagnostics Market Value Share Analysis, By End-user, 2024 and 2035
Figure 65: Middle East & Africa Gastric Cancer Diagnostics Market Attractiveness Analysis, By End-user, 2025 to 2035